Mitogen activated protein kinase phosphatases and cancer

Cancer Biology and Therapy

Volumn 9, Issue 5, 2010, Pages 337-340

  Haagenson, Kelly K ^a   Wu, Gen Sheng ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Dual specificity phosphatases; MAPK signaling; MKP 1; MKP 2; MKP 3

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 6; MDF 2085; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 2; NSC 95397; PSI 2106; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; THREONINE; TRIPTOLIDE; TYROSINE; UNCLASSIFIED DRUG;

CARCINOGENESIS; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME SPECIFICITY; HUMAN; NEOPLASM; PROTEIN EXPRESSION; PROTEIN MOTIF; REVIEW;

CELL DEATH; CELL PROLIFERATION; DUAL SPECIFICITY PHOSPHATASE 1; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; NERVOUS SYSTEM NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77953724992     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.5.11217     Document Type: Review

References (33)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Wu GS. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 2007; 26:579-85.
3. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death and cancer. Pharmacol Rev 2008; 60:261-310.
4. Wang J, Zhou JY, Wu GS. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 2007; 67:11933-41.
5. Zhou JY, Liu Y, Wu GS. The role of mitogen-activated protein kinase phosphatase-1 in oxidative damage-induced cell death. Cancer Res 2006; 66:4888-94.
6. Dickinson RJ, Keyse SM. Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 2006; 119:4607-15.
7. Keyse SM, Ginsburg M. Amino acid sequence similarity between CL100, a dual-specificity MAP kinase phosphatase and cdc25. Trends Biochem Sci 1993; 18:377-8.
8. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases - regulating the immune response. Nat Rev Immunol 2007; 7:202-12.
9. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008; 27:253-61.
10. Koukourakis MI, Giatromanolaki A, Sheldon H, Buffa FM, Kouklakis G, Ragoussis I, et al. Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clin Cancer Res 2009; 15:7069-76.
11. Denkert C, Schmitt WD, Berger S, Reles A, Pest S, Siegert A, et al. Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 2002; 102:507-13.
12. Wang Z, Xu J, Zhou JY, Liu Y, Wu GS. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res 2006; 66:8870-7.
13. Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007; 67:4459-66.
14. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 2000; 14:6-16. (Pubitemid 30051518)
15. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003; 191:229-37.
16. Yokoyama A, Karasaki H, Urushibara N, Nomoto K, Imai Y, Nakamura K, et al. The characteristic gene expressions of MAPK phosphatases 1 and 2 in hepatocarcinogenesis, rat ascites hepatoma cells, and regenerating rat liver. Biochem Biophys Res Commun 1997; 239:746-51.
17. Yip-Schneider MT, Lin A, Marshall MS. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun 2001; 280:992-7.
18. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003; 162:1807-15. (Pubitemid 36613039)
19. Furukawa T, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol 2005; 18:1034-42.
20. Warmka JK, Mauro LJ, Wattenberg EV. Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras. J Biol Chem 2004; 279:33085-92.
21. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, et al. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 2006; 66:5950-9.
22. Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, et al. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 2008; 29:1742-50.
23. Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Trope CG, Reich R. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol 2004; 93:517-23.
24. Christie GR, Williams DJ, Macisaac F, Dickinson RJ, Rosewell I, Keyse SM. The dual-specificity protein phosphatase DUSP9/MKP-4 is essential for placental function but is not required for normal embryonic development. Mol Cell Biol 2005; 25:8323-33.
25. Liu Y, Lagowski J, Sundholm A, Sundberg A, Kulesz-Martin M. Microtubule disruption and tumor suppression by mitogen-activated protein kinase phosphatase 4. Cancer Res 2007; 67:10711-9.
26. Hoornaert I, Marynen P, Goris J, Sciot R, Baens M. MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL- induced transformation. Oncogene 2003; 22:7728-36.
27. Zaidi SK, Dowdy CR, van Wijnen AJ, Lian JB, Raza A, Stein JL, et al. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network. Cancer Res 2009; 69:8249-55.
28. Wang Z, Zhou JY, Kanakapalli D, Buck S, Wu GS, Ravindranath Y. High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma. Pediatr Blood Cancer 2008; 51:754-9.
29. Wang J, Zhou JY, Zhang L, Wu GS. Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 2009; 8:3191-8.
30. Vogt A, Lazo JS. Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases. Methods 2007; 42:268-77.
31. Vogt A, McDonald PR, Tamewitz A, Sikorski RP, Wipf P, Skoko JJ, et al. A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther 2008; 7:330-40.
32. Arnold DM, Foster C, Huryn DM, Lazo JS, Johnston PA, Wipf P. Synthesis and biological activity of a focused library of mitogen-activated protein kinase phosphatase inhibitors. Chem Biol Drug Des 2007; 69:23-30.
33. Lazo JS, Skoko JJ, Werner S, Mitasev B, Bakan A, Koizumi F, et al. Structurally unique inhibitors of human mitogen-activated protein kinase phosphatase-1 identified in a pyrrole carboxamide library. J Pharmacol Exp Ther 2007; 322:940-7.